25 results
8-K
MLYS
Mineralys Therapeutics Inc
10 Jun 24
Other Events
4:02pm
the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy … Phase 3 clinical trial to evaluate the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN, when used as an add-on therapy
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add … to evaluate the safety and efficacy of lorundrostat as a potential therapy to treat patients with Stage 2 to 3b CKD was updated in the first quarter to allow
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
of the two ongoing pivotal trials, the Advance-HTN trial is evaluating the safety and efficacy of lorundrostat for the treatment of uHTN or rHTN, when used … and obtain additional safety and efficacy data.
BMI Data from Target-HTN Phase 2 Trial – The Company presented data from a new analysis of serum leptin
8-K
EX-99.1
4r127q85jaemfrnkxo
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
q3v30ce01v7
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
EX-99.1
gvclb io5fg7wn09u0o
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
EX-99.1
8lcwr
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
2y9iu0q90y2nk9
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
EX-99.1
24de2s41r5 njhhkwd
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
kleis 7x5epw
17 Jul 23
Regulation FD Disclosure
4:03pm
10-Q
q9a447y
15 May 23
Quarterly report
5:25pm
8-K
EX-99.1
08q46x qflq6
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
8ceox xazm2cravrj
2 May 23
Other Events
8:09am
DRS/A
gwuf31j4u82js 0e9z4
29 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
byh1q0f2ipq9qb8ah1s
7 Dec 22
Draft registration statement (amended)
12:00am
DRSLTR
7vxo8ptoie s4ro7iiic
6 Dec 22
Correspondence regarding draft registration statement
12:00am